Attrition from care and its predictors among women exposed to dolutegravir- and efavirenz-based first-line antiretroviral therapy in Ethiopia: a before-and-after study
Frontiers in Public Health · 2024
DOI: 10.3389/fpubh.2024.1385441 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Public Health, 2024. Verfasst von Wolde Facha und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology and Biostatistics, School of Public Health, College of Health Sciences and Medicine, Wolaita Sodo University, Wolaita Sodo…. Hauptthemen laut MEDLINE: Cyclopropanes, Benzoxazines, Alkynes, HIV Infections. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
The effect of dolutegravir (DTG)-based regimens on reducing attrition from care among women enrolled in the prevention of mother-to-child transmission (PMTCT) care program is unknown. Therefore, this study aimed to compare the incidence of attrition among women exposed to DTG-based with those exposed to efavirenz (EFV)-based first-line antiretroviral therapy (ART) in Ethiopia.
Methods
An uncontrolled before-and-after study was conducted involving 932 women (with 466 on EFV-based and 466 on DTG-based regimens) who were enrolled in the PMTCT care program from September 2015 to February 2023. The outcome variable was attrition (i.e., maternal death or loss to follow-up before their infants' final HIV status was determined). A Kaplan–Meier estimator was employed to estimate the probability of attrition. The Cox proportional hazards regression model was fitted to identify predictor variables. The adjusted hazard ratio (aHR) with the corresponding 95% confidence interval (CI) was calculated to examine the risk difference in the comparison groups.
Results
The cumulative incidence of attrition among women was 5.2% (3.0% for those placed in the DTG-based regimen arm and 7.3% for those placed in the EFV-based regimen arm). Women on DTG-based regimens had a 57% (aHR: 0.43; 95% CI: 0.23–0.80) lower risk of attrition from care compared to those on EFV-based regimens. Women who delivered their infants at home (aHR: 2.35; 95% CI: 1.14–4.85), had poor/fair adherence (aHR: 3.23; 95% CI: 1.62–6.45), had unsuppressed/unknown viral load status (aHR: 2.61; 95% CI: 1.42–4.79), and did not disclose their status to partners (aHR: 2.56; 95% CI: 1.34–4.92) had a higher risk of attrition from PMTCT care compared to their counterparts.
Conclusion
The cumulative incidence of attrition among women receiving PMTCT care is optimal. In addition, the risk of attrition among women receiving DTG-based regimens is lower than that among women receiving EFV-based regimens. Thus, DTG-based first-line ART regimen supplementation should be sustained to achieve a national retention target of 95% and above.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Epidemiology and Biostatistics, School of Public Health, College of Health Sciences and Medicine, Wolaita Sodo University, Wolaita Sodo, Ethiopia.
- School of Public Health, College of Medicine and Health Sciences, Hawassa University, Hawassa, Ethiopia.
Zitieren
APA
Facha, W., Tadesse, T., Wolka, E., & Astatkie, A. (2024). Attrition from care and its predictors among women exposed to dolutegravir- and efavirenz-based first-line antiretroviral therapy in Ethiopia: a before-and-after study. Frontiers in Public Health. https://doi.org/10.3389/fpubh.2024.1385441
Vancouver
Facha W, Tadesse T, Wolka E, Astatkie A. Attrition from care and its predictors among women exposed to dolutegravir- and efavirenz-based first-line antiretroviral therapy in Ethiopia: a before-and-after study. Frontiers in Public Health. 2024. doi:10.3389/fpubh.2024.1385441
BibTeX
@article{Facha2024,
author = {Facha, Wolde and Tadesse, Takele and Wolka, Eskinder and Astatkie, Ayalew},
title = {Attrition from care and its predictors among women exposed to dolutegravir- and efavirenz-based first-line antiretroviral therapy in Ethiopia: a before-and-after study},
journal = {Frontiers in Public Health},
year = {2024},
doi = {10.3389/fpubh.2024.1385441}
}
EUVIMED